Identification of three antiviral inhibitors against Japanese encephalitis virus from library of pharmacologically active compounds 1280

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Fang, Jin'e ^a   Sun, Leqiang ^a   Peng, Guiqing ^a   Xu, Jia ^a   Zhou, Rui ^a   Cao, Shengbo ^a   Chen, Huanchun ^a   Song, Yunfeng ^a  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CILNIDIPINE; FGIN 1 27; N,N DIHEXYL 2(4 FLUOROPHENYL)INDOLE 3 ACETAMIDE; NICLOSAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; IMMUNOFLUORESCENCE TEST; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; DIHYDROPYRIDINES; ENCEPHALITIS VIRUS, JAPANESE; FLUORESCENT ANTIBODY TECHNIQUE; INDOLEACETIC ACIDS; NICLOSAMIDE;

EID: 84892611018     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078425     Document Type: Article

References (32)

1. Barrett AD (2008) Japanese encephalitis virus. In: Mahy WJ, van Regenmortel MVH, Encyclopaedia of Virology. Oxford: Elsevier Press. 182-188.
2. Mukhopadhyay S, Kuhn RJ, Rossmann MG (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3: 13-22.
3. Mackenzie JS, Gubler DJ, Petersen LR (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: S98-109.
4. Hanna JN, Ritchie SA, Phillips DA, Lee JM, Hills SL, et al. (1999) Japanese encephalitis in north Queensland, Australia, 1998. Med J Aust 170: 533-536.
5. Mackenzie JS, Johansen CA, Ritchie SA, van den Hurk AF, Hall RA (2002) Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia. Curr Top Microbiol Immunol 267: 49-73.
6. Igarashi A, Tanaka M, Morita K, Takasu T, Ahmed A, et al. (1994) Detection of west Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol Immunol 38: 827-830.
7. Mitchell CJ, Savage HM, Smith GC, Flood SP, Castro LT, et al. (1993) Japanese encephalitis on Saipan: a survey of suspected mosquito vectors. Am J Trop Med Hyg 48: 585-590.
8. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, et al. (1988) Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319: 608-614.
9. Xin YY, Ming ZG, Peng GY, Jian A, Min LH (1988) Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg 39: 214-217.
10. Ku CC, King CC, Lin CY, Hsu HC, Chen LY, et al. (1994) Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children. J Med Virol 44: 122-131.
11. Wang LH, Fu SH, Wang HY (2007) Japanese Encephalitis Outbreak, Yuncheng, China, 2006. Emerg Infect Dis 13: 1123-1125.
12. Gould EA, Solomon T, Mackenzie JS (2008) Does antiviral therapy have a role in the control of Japanese encephalitis? Antiviral Res 78: 140-149.
13. Enserink M (2011) First specific drugs raise hopes for hepatitis C. Science 332: 159-160.
14. Shi PY (2002) Strategies for the identification of inhibitors of West Nile virus and other flaviviruses. Curr Opin Investig Drugs 3: 1567-1573.
15. Noble CG, Chen YL, Dong H, Gu F, Lim SP, et al. (2010) Strategies for development of Dengue virus inhibitors. Antiviral Res 85: 450-462.
16. Chang SJ, Chang YC, Lu KZ, Tsou YY, Lin CW (2012) Antiviral activity of Isatis indigotica extract and its derived indirubin against Japanese encephalitis virus. Evid. Based Complement Alternat Med 2012: 925830.
17. Chang CC, Ou YC, Raung SL, Chen CJ (2005) Antiviral effect of dehydroepiandrosterone on Japanese encephalitis virus infection. J Gen Virol 86: 2513-2523.
18. Wu SF, Lee CJ, Liao CL, Dwek RA, Zitzmann N, et al. (2002) Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol 76: 3596-3604.
19. Sebastian L, Desai A, Shampur MN, Perumal Y, Sriram D, et al. (2008) N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo. Virol J 5: 64.
20. Che P, Wang L, Li Q (2009) The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus. Int J Clin Exp Med 2: 363-373.
21. Severson WE, Shindo N, Sosa M, Fletcher T 3rd, White EL, et al. (2007) Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library. J Biomol Screen 12: 33-40.
22. Chen Z, Shao L, Ye J, Li Y, Huang S, et al. (2012) Monoclonal antibodies against NS3 and NS5 proteins of Japanese encephalitis virus. Hybridoma (Larchmt) 31: 137-141.
23. Yang KD, Yeh WT, Chen RF, Chuon HL, Tsai HP, et al. (2004) A model to study neurotropism and persistency of Japanese encephalitis virus infection in human neuroblastoma cells and leukocytes. J Gen Virol 85: 635-642.
24. Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, et al. (2011) Identification of a small-molecule entry inhibitor for filoviruses. J Virol 85: 3106-3119.
25. Botting C, Kuhn RJ (2012) Novel approaches to flavivirus drug discovery. Expert Opin Drug Discov 7: 417-428.
26. Junaid M, Chalayut C, Sehgelmeble Torrejon A, Angsuthanasombat C, Shutava I, et al. (2012) Enzymatic analysis of recombinant Japanese encephalitis virus NS2B(H)-NS3pro protease with fluorogenic model peptide substrates. PLoS One 7: e36872.
27. Boguszewska-Chachulska AM, Krawczyk M, Stankiewicz A, Gozdek A, Haenni AL, et al. (2004) Direct fluorometric measurement of hepatitis C virus helicase activity. FEBS Lett 567: 253-258.
28. Ogura C, Ono K, Miyamoto S, Ikai A, Mitani S, et al. (2012) L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension. Blood Press 21: 367-371.
29. Morimoto S, Yano Y, Maki K, Iwasaka T (2007) Renal and vascular protective effects of Cilnidipine in patients with essential hypertension. J Hypertens 25: 2178-2183.
30. Xu G, Wu H, Du B, Qin L (2012) The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients. Cardiovasc Hematol Disord Drug Targets 12: 56-62.
31. Romeo E, Cavallaro S, Korneyev A, Kozikowski AP, Ma D, et al. (1993) Stimulation of brain steroidogenesis by 2-aryl-indole-3-acetamide derivatives acting at the mitochondrial diazepam-binding inhibitor receptor complex. J Pharmacol Exp Ther 267: 462-471.
32. Romeo E, Auta J, Kozikowski AP, Ma D, Papadopoulos V, et al. (1992) 2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR). J Pharmacol Exp Ther 262: 971-978.